Kronos Bio, Inc. (KRON)
Largest Insider Buys in Sector
KRON Stock Price History Chart
KRON Stock Performance
About Kronos Bio, Inc.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy …
Insider Activity of Kronos Bio, Inc.
Over the last 12 months, insiders at Kronos Bio, Inc. have bought $5.32M and sold $104,531 worth of Kronos Bio, Inc. stock.
On average, over the past 5 years, insiders at Kronos Bio, Inc. have bought $12.93M and sold $1.93M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BISCHOFBERGER NORBERT W (President & CEO) — $10.65M.
The last purchase of 204,670 shares for transaction amount of $254,957 was made by BISCHOFBERGER NORBERT W (PRESIDENT & CEO) on 2024‑06‑28.
List of Insider Buy and Sell Transactions, Kronos Bio, Inc.
| 2024-06-28 | PRESIDENT & CEO | 204,670 0.4456% | $1.25 | $254,957 | 0.00% | |||
| 2024-06-27 | PRESIDENT & CEO | 410,848 0.8369% | $1.17 | $478,843 | 0.00% | |||
| 2024-06-12 | PRESIDENT & CEO | 881,913 1.586% | $1.24 | $1.1M | -22.44% | |||
| 2024-06-11 | PRESIDENT & CEO | 744,308 1.1787% | $1.09 | $814,571 | -13.56% | |||
| 2024-06-10 | PRESIDENT & CEO | 1.38M 2.1146% | $0.88 | $1.21M | +4.66% | |||
| 2024-02-21 | Sale | SR VP, RESEARCH & DEVELOPMENT | 12,036 0.0205% | $1.05 | $12,685 | -2.86% | ||
| 2024-02-21 | Sale | SR VP, CORP OPERATIONS & LEGAL | 12,105 0.0206% | $1.05 | $12,757 | -2.86% | ||
| 2024-02-21 | Sale | SR VP, CLINICAL SCIENCE | 7,368 0.0126% | $1.05 | $7,765 | -2.86% | ||
| 2024-01-04 | Sale | COO & General Counsel | 10,676 0.0179% | $1.18 | $12,636 | -14.05% | ||
| 2024-01-04 | Sale | Chief Medical Officer & VP | 12,009 0.0201% | $1.18 | $14,214 | -14.05% | ||
| 2024-01-04 | Sale | Chief Scientific Officer | 7,366 0.0124% | $1.18 | $8,718 | -14.05% | ||
| 2023-12-12 | Sale | Chief Medical Officer & VP | 17,367 0.0299% | $1.30 | $22,664 | -19.23% | ||
| 2023-12-12 | Sale | Chief Scientific Officer | 10,032 0.0173% | $1.30 | $13,092 | -19.23% | ||
| 2023-11-17 | President & CEO | 97,935 0.167% | $1.08 | $106,162 | -1.85% | |||
| 2023-11-16 | President & CEO | 262,433 0.4271% | $1.00 | $261,514 | +0.47% | |||
| 2023-11-15 | President & CEO | 1.37M 2.1008% | $0.80 | $1.1M | +17.76% | |||
| 2023-07-06 | Sale | Chief Financial Officer | 9,617 0.0159% | $1.75 | $16,852 | -36.56% | ||
| 2023-07-06 | Sale | Chief Medical Officer & VP | 10,818 0.0178% | $1.75 | $18,956 | -36.56% | ||
| 2023-07-06 | Sale | Chief Scientific Officer | 6,634 0.0109% | $1.75 | $11,625 | -36.56% | ||
| 2023-02-24 | Sale | Chief Financial Officer | 9,026 0.0167% | $1.74 | $15,665 | -19.76% |
Insider Historical Profitability
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 10802138 17.9156% | $0.94 | 11 | 0 | <0.0001% |
| Kosacz Barbara | COO & General Counsel | 928966 1.5407% | $0.94 | 1 | 1 | <0.0001% |
| Dinsmore Christopher | Chief Scientific Officer | 260969 0.4328% | $0.94 | 1 | 9 | <0.0001% |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10 percent owner | 4370496 7.2486% | $0.94 | 1 | 0 | <0.0001% |
| Stampacchia Otello | 3818283 6.3327% | $0.94 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Bvf Inc Il | $3.78M | 4.83 | 2.91M | 0% | +$0 | 0.03 | |
| Vida Ventures Advisors Llc | $3.59M | 4.6 | 2.77M | 0% | +$0 | 2 | |
| The Vanguard Group | $2.53M | 3.24 | 1.95M | +14.58% | +$322,293.34 | <0.0001 | |
| Millennium Management LLC | $2.38M | 3.04 | 1.83M | +115.53% | +$1.27M | <0.01 | |
| Alphabet | $1.87M | 2.39 | 1.44M | 0% | +$0 | 0.02 |